US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
AU5772886A
(en)
|
1985-04-12 |
1986-11-05 |
Genetics Institute Inc. |
Novel procoagulant proteins
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
EP0253870B1
(de)
|
1986-01-03 |
1993-03-31 |
Genetics Institute, Inc. |
Verfahren zur herstellung von faktor-viii:c-typ-proteinen
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
US5451521A
(en)
*
|
1986-05-29 |
1995-09-19 |
Genetics Institute, Inc. |
Procoagulant proteins
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
WO1988005825A1
(en)
†
|
1987-01-30 |
1988-08-11 |
Biogen N.V. |
A method for producing factor viii in high yield
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
CA1331157C
(en)
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Method for producing factor viii:c-type proteins
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
IL86693A
(en)
|
1987-06-12 |
1994-06-24 |
Stichting Centraal Lab |
Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
|
EP0294910B1
(de)
†
|
1987-06-12 |
1996-09-11 |
Immuno Ag |
Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US5004803A
(en)
|
1988-11-14 |
1991-04-02 |
Genetics Institute, Inc. |
Production of procoagulant proteins
|
ATE135370T1
(de)
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
EP0461200B1
(de)
|
1989-02-21 |
1997-01-22 |
Washington University |
Modifizierte formen von fortpflanzungshormonen
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
JP3693671B2
(ja)
|
1991-03-15 |
2005-09-07 |
アムゲン インコーポレーテッド |
ポリペプチドのpeg化
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
DE69626829T2
(de)
†
|
1995-08-04 |
2004-03-18 |
Lek Farmacevtska Druzba D.D. |
Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
CA2262405A1
(en)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
EP1006183A1
(de)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rekombinante, lösliche Fc-Rezeptoren
|
CA2359067C
(en)
|
1999-01-15 |
2017-03-14 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
HU228091B1
(en)
†
|
2000-03-22 |
2012-10-29 |
Octapharma Biopharmaceuticals Gmbh |
Production of recombinant blood clotting factors in human cell lines
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
EP2277910A1
(de)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin Fusionsproteine
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
AU2003209446B2
(en)
|
2002-03-01 |
2008-09-25 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
WO2003077834A2
(en)
|
2002-03-15 |
2003-09-25 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
EP1562972B1
(de)
|
2002-10-15 |
2010-09-08 |
Facet Biotech Corporation |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7041635B2
(en)
†
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
AU2004239244C1
(en)
|
2003-05-06 |
2015-04-23 |
Bioverativ Therapeutics Inc. |
Clotting factor-Fc chimeric proteins to treat hemophilia
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
EP2385069A3
(de)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonataler Fc-Rezeptor (FcRn)-bindende Polypeptidvarianten, dimere Fc-Bindungsproteine und damit in Zusammenhang stehende Verfahren
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
Fc領域変異体
|
EP2053062A1
(de)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobinvarianten außerhalb der Fc-Region
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
KR100863776B1
(ko)
|
2004-07-15 |
2008-10-16 |
젠코어 인코포레이티드 |
최적화된 Fc 변이체
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
SI3130601T1
(sl)
|
2004-11-12 |
2020-11-30 |
Bayer Healthcare Llc |
Usmerjena modifikacija FVIII
|
US7351582B2
(en)
†
|
2005-06-17 |
2008-04-01 |
Avigenics, Inc. |
Cell lines
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
WO2007103515A2
(en)
|
2006-03-06 |
2007-09-13 |
Amunix, Inc. |
Unstructured recombinant polymers and uses thereof
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
SI2173890T1
(sl)
|
2007-06-21 |
2011-06-30 |
Univ Muenchen Tech |
Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
|
MX2010001684A
(es)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
BR122021021381B1
(pt)
|
2009-02-03 |
2023-05-16 |
Amunix Pharmaceuticals, Inc |
Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
|
WO2011032284A1
(en)
†
|
2009-09-16 |
2011-03-24 |
University Of Saskatchewan |
Steroidogenesis modified cells and methods for screening for endocrine disrupting chemicals
|
PT2482841T
(pt)
*
|
2009-10-02 |
2019-03-01 |
Childrens Hospital Philadelphia |
A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
|
NZ703153A
(en)
†
|
2009-12-06 |
2015-02-27 |
Biogen Idec Hemophilia Inc |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
EP2591101B1
(de)
*
|
2010-07-09 |
2018-11-07 |
Bioverativ Therapeutics Inc. |
Systeme für faktor viii-verarbeitung und verfahren davon
|
LT3513804T
(lt)
|
2011-07-08 |
2022-05-25 |
Bioverativ Therapeutics Inc. |
Viii faktorius chimeriniai ir hibridiniai polipetidai bei jų panaudojimo būdai
|
MY201293A
(en)
|
2012-01-12 |
2024-02-15 |
Bioverativ Therapeutics Inc |
Chimeric factor viii polypeptides and uses thereof
|
EP2870250B2
(de)
†
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
|
CA2878679A1
(en)
†
|
2012-07-11 |
2014-01-16 |
Amunix Operating Inc. |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
SG10201710616XA
(en)
†
|
2013-06-28 |
2018-02-27 |
Biogen Ma Inc |
Thrombin cleavable linker with xten and its uses thereof
|
WO2014210547A1
(en)
†
|
2013-06-28 |
2014-12-31 |
Biogen Idec Ma Inc. |
Thrombin cleavable linker
|